239 related articles for article (PubMed ID: 33144375)
21. Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease.
Lambert-Niclot S; Flandre P; Malet I; Canestri A; Soulié C; Tubiana R; Brunet C; Wirden M; Katlama C; Calvez V; Marcelin AG
J Antimicrob Chemother; 2008 Nov; 62(5):905-8. PubMed ID: 18765410
[TBL] [Abstract][Full Text] [Related]
22. Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain.
Martins AN; Waheed AA; Ablan SD; Huang W; Newton A; Petropoulos CJ; Brindeiro RD; Freed EO
J Virol; 2016 Jan; 90(2):768-79. PubMed ID: 26512081
[TBL] [Abstract][Full Text] [Related]
23. Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor.
Ho SK; Perez EE; Rose SL; Coman RM; Lowe AC; Hou W; Ma C; Lawrence RM; Dunn BM; Sleasman JW; Goodenow MM
AIDS; 2009 Aug; 23(13):1631-40. PubMed ID: 19625947
[TBL] [Abstract][Full Text] [Related]
24. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
Maguire MF; Guinea R; Griffin P; Macmanus S; Elston RC; Wolfram J; Richards N; Hanlon MH; Porter DJ; Wrin T; Parkin N; Tisdale M; Furfine E; Petropoulos C; Snowden BW; Kleim JP
J Virol; 2002 Aug; 76(15):7398-406. PubMed ID: 12097552
[TBL] [Abstract][Full Text] [Related]
25. The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor-Resistant Clinical Isolates.
Ray N; Li T; Lin Z; Protack T; van Ham PM; Hwang C; Krystal M; Nijhuis M; Lataillade M; Dicker I
J Acquir Immune Defic Syndr; 2017 May; 75(1):52-60. PubMed ID: 28234686
[TBL] [Abstract][Full Text] [Related]
26. Mutational patterns in the frameshift-regulating site of HIV-1 selected by protease inhibitors.
Knops E; Brakier-Gingras L; Schülter E; Pfister H; Kaiser R; Verheyen J
Med Microbiol Immunol; 2012 May; 201(2):213-8. PubMed ID: 22200908
[TBL] [Abstract][Full Text] [Related]
27. HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat.
Fun A; van Maarseveen NM; Pokorná J; Maas RE; Schipper PJ; Konvalinka J; Nijhuis M
Retrovirology; 2011 Aug; 8():70. PubMed ID: 21864346
[TBL] [Abstract][Full Text] [Related]
28. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss.
Dam E; Quercia R; Glass B; Descamps D; Launay O; Duval X; Kräusslich HG; Hance AJ; Clavel F;
PLoS Pathog; 2009 Mar; 5(3):e1000345. PubMed ID: 19300491
[TBL] [Abstract][Full Text] [Related]
29. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
Nijhuis M; van Maarseveen NM; Lastere S; Schipper P; Coakley E; Glass B; Rovenska M; de Jong D; Chappey C; Goedegebuure IW; Heilek-Snyder G; Dulude D; Cammack N; Brakier-Gingras L; Konvalinka J; Parkin N; Kräusslich HG; Brun-Vezinet F; Boucher CA
PLoS Med; 2007 Jan; 4(1):e36. PubMed ID: 17227139
[TBL] [Abstract][Full Text] [Related]
30. Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response.
Ho SK; Coman RM; Bunger JC; Rose SL; O'Brien P; Munoz I; Dunn BM; Sleasman JW; Goodenow MM
Virology; 2008 Sep; 378(2):272-81. PubMed ID: 18599104
[TBL] [Abstract][Full Text] [Related]
31. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.
Masquelier B; Breilh D; Neau D; Lawson-Ayayi S; Lavignolle V; Ragnaud JM; Dupon M; Morlat P; Dabis F; Fleury H;
Antimicrob Agents Chemother; 2002 Sep; 46(9):2926-32. PubMed ID: 12183249
[TBL] [Abstract][Full Text] [Related]
32. Gag P2/NC and pol genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02_AG- and non-CRF02_AG-infected patients in Yaoundé, Cameroon.
Teto G; Tagny CT; Mbanya D; Fonsah JY; Fokam J; Nchindap E; Kenmogne L; Njamnshi AK; Kanmogne GD
Sci Rep; 2017 Oct; 7(1):14136. PubMed ID: 29074854
[TBL] [Abstract][Full Text] [Related]
33. Drug susceptibility and replication capacity of a rare HIV-1 subtype C protease hinge region variant.
Zondagh J; Basson AE; Achilonu I; Morris L; Dirr HW; Sayed Y
Antivir Ther; 2019; 24(5):333-342. PubMed ID: 30958309
[TBL] [Abstract][Full Text] [Related]
34. Modeling the full length HIV-1 Gag polyprotein reveals the role of its p6 subunit in viral maturation and the effect of non-cleavage site mutations in protease drug resistance.
Su CT; Kwoh CK; Verma CS; Gan SK
J Biomol Struct Dyn; 2018 Dec; 36(16):4366-4377. PubMed ID: 29237328
[TBL] [Abstract][Full Text] [Related]
35. Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients.
Giandhari J; Basson AE; Coovadia A; Kuhn L; Abrams EJ; Strehlau R; Morris L; Hunt GM
AIDS Res Hum Retroviruses; 2015 Aug; 31(8):776-82. PubMed ID: 25919760
[TBL] [Abstract][Full Text] [Related]
36. Genetic diversity in the partial sequence of the HIV-1 gag gene among people living with multidrug-resistant HIV-1 infection.
Alencar CS; Sabino EC; Diaz RS; Mendrone-Junior A; Nishiya AS
Rev Inst Med Trop Sao Paulo; 2024; 66():e35. PubMed ID: 38865573
[TBL] [Abstract][Full Text] [Related]
37. Double trouble? Gag in conjunction with double insert in HIV protease contributes to reduced DRV susceptibility.
Williams A; Basson A; Achilonu I; Dirr HW; Morris L; Sayed Y
Biochem J; 2019 Jan; 476(2):375-384. PubMed ID: 30573649
[TBL] [Abstract][Full Text] [Related]
38. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
[TBL] [Abstract][Full Text] [Related]
39. Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays.
Gupta RK; Kohli A; McCormick AL; Towers GJ; Pillay D; Parry CM
AIDS; 2010 Jul; 24(11):1651-5. PubMed ID: 20597164
[TBL] [Abstract][Full Text] [Related]
40. Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat.
Margot NA; Gibbs CS; Miller MD
Antimicrob Agents Chemother; 2010 Jun; 54(6):2345-53. PubMed ID: 20308382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
